Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Hemorrhagic shock is a rare condition which occurs in many gynecological or obstetrical situations. In this condition, reduction in blood volume leads to sympathetic compensation by tachycardia, peripheral vasoconstriction, and increased myocardial contractility. This can increase the myocardial oxygen demand. As per the World Health Organization (WHO), trauma remains one of the leading causes of death globally with half of the cases attributed to hemorrhages.
According to the National Trauma Institute (NTI), trauma is the third leading cause of mortality across the globe in the age group ranging from 1 to 44 years. Major hemorrhage is responsible for 30-40% mortality among trauma patients. Moreover, in patients with traumatic injuries to the central nervous system, hemorrhagic shock is the second leading cause of morbidity and mortality despite the fact that it could be reversible and preventable.
The growing burden of chronic diseases and the increase in consumption of anti-hypertensive drugs is expected to drive the growth of the global hemorrhagic shock treatment market during the forecast period. For instance, according to the World Health Organization (WHO), the rate of chronic disease burden is estimated to increase from 47% in 2001 to 57% by 2020.
Hemorrhagic Shock Treatment Market - Impact of Coronavirus (Covid-19) Pandemic
The ongoing COVID-19 pandemic is posing major challenges in the management of important medical emergencies such as hemorrhage and other chronic conditions. Hemorrhagic shock is an important health emergency with significant morbidity and mortality and needs timely treatment. However, higher COVID-19 cases, lack of facilities, and infrastructure is posing challenge for the healthcare system to treat patients with other morbidities.
The all-inclusive version of the report will include the impact of COVID-19 and the probable changes in the future outlook of the industry, by taking into account the technological, social, political, and economical parameters.
The global hemorrhagic shock treatment market is estimated to be valued at US$ 175.4 million in 2020 and is expected witness a CAGR of 4.0% during the forecast period (2020-2027).
Figure 1: Global Hemorrhagic Shock Treatment Market Share (%) Analysis, By Distribution Channel, 2020.
An increase in the number of clinical trials and collaborative agreements for hemorrhagic shock treatment are expected to propel the growth of the global hemorrhagic shock treatment market.
Key players in the market are involved in research & d evelopment of therapies and drugs for the treatment of hemorrhagic shock. Strategic collaborations, licensing agreements, and drug approvals are expected to drive growth of the global hemorrhagic shock treatment market during the forecast period.
In February 2015, Leading BioSciences received FDA IND clearance for phase II clinical trial using LB1148 (tranexamic acid) for the treatment of hemorrhagic shock. According to the company, the U.S. Food and Drug Administration (FDA) approval for conducting a well-designed phase II safety and efficacy trial for LB-1148 is a crucial step in advancing the company’s development plan.
In January 2017, NuvOxPharma LLC and Jiangsu Nhwa Pharmaceutical Co., Ltd. entered a licensing agreement for the development and sales of NVX-408 in China for treatment of perioperative blood loss and hemorrhagic shock. NVX-408 is injected intravenously and is an oxygen therapeutic that flows through the lungs and collects oxygen, then flowing through the blood passing hypoxic tissue and releases oxygen. According to pre-clinical studies, NVX-408 can improve survival rate during severe blood loss.
Global Hemorrhagic Shock Treatment Market - Restraints
The dearth of healthcare services and costs associated with the treatment of hemorrhagic shock are major factors restraining the growth of the market across the globe. Moreover, the lack of advanced healthcare facilities in low- and mid-income countries in Africa is expected to hamper the overall market growth.
Hemorrhagic Shock Treatment Market Report Coverage
||Market Size in 2019:
||US$ 175.4 Mn
|Historical Data for:
||2016 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 230.9 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Drug: NVX-408, YW-356, LB-1148, Neutrolide, Others.
- By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Channels.
Biomedica Management Corporation, NuvOxPharma LLC, Leading BioSciences, Inc., F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Johnson & Johnson Services Inc, AstraZeneca, Daiichi Sankyo Company, Limited, Teva Pharmaceutical Industries Ltd, Novartis AG, ZydusCadila, and Amneal Pharmaceuticals LLC.
- The growing burden of chronic diseases
- Changes in lifestyle and rising consumption of anti-hypertensive drugs
|Restraints & Challenges:
- High costs associated with the hemorrhagic shock treatment
- Stringent regulatory for using hemorrhagic shock drug
Global Hemorrhagic Shock Treatment Market – Regional Analysis
The market North America accounted for the largest share in the hemorrhagic shock treatment in 2019 due to the growing demand for disease-specific treatment, the increasing focus on research & development, and approvals for the treatment of hemorrhagic shock. For instance, in February 2017, the U.S. Army Institute of Surgical Research (USAISR) received FDA clearance for its hemorrhagic shock device. The researchers of USAISR collaborated with engineers and scientists at the University of Colorado and Flashback Technologies Inc. to develop an algorithm to detect when a patient is going into hemorrhagic shock. The tiny device is the first medical monitoring technology capable of early detection of impending circulatory shock in trauma patients.
In October 2019, scientists at the Feinstein Institutes for Medical Research completed a study that involves bio-electronic medicine strategies for hemorrhagic shock (HS) treatment. The positive findings of this study have been published in the Springer Nature journal.
Figure 2: Global Hemorrhagic Shock Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027
Global Hemorrhagic Shock Treatment Market - Competitive Landscape
Key players operating in the global hemorrhagic shock treatment market are Biomedica Management Corporation, NuvOxPharma LLC, Leading BioSciences, Inc., F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH,Johnson & Johnson Services Inc, AstraZeneca, Daiichi Sankyo Company, Limited, Teva Pharmaceutical Industries Ltd, Novartis AG, ZydusCadila, and Amneal Pharmaceuticals LLC.